<DOC>
	<DOCNO>NCT00618813</DOCNO>
	<brief_summary>This clinical trial study side effect combination chemotherapy see well work treat patient newly diagnose localize Ewing sarcoma family tumor . Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) give drug different way may kill tumor cell .</brief_summary>
	<brief_title>Two Regimens Combination Chemotherapy Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess feasibility safety add interval-compressed vincristine , topotecan hydrochloride , cyclophosphamide treatment protocol utilize interval compression vincristine , doxorubicin hydrochloride , cyclophosphamide , ifosfamide , etoposide patient localize Ewing sarcoma family tumor . SECONDARY OBJECTIVES : I . To estimate event-free survival patient treat regimen . OUTLINE : This multicenter study . INDUCTION THERAPY ( WEEKS 1-12 ) : Patients receive vincristine IV day 1 week 1 , 2 , 5 , 6 , 9 , 10 , 11 , 12 ; topotecan hydrochloride IV 30 minute day 1-5 week 1 9 ; cyclophosphamide IV 1 hour day 1-5 week 1 9 day 1 week 5 11 ; ifosfamide IV 1 hour day 1-5 week 3 7 ; etoposide IV 1 hour day 1-5 week 3 7 ; doxorubicin hydrochloride IV 15 minute day 1 2 week 5 11 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin 24-36 hour last dose chemotherapy continue least 7 day blood count recover , whichever come last . Filgrastim discontinue least 24 hour prior next course chemotherapy . LOCAL CONTROL : Patients respond induction therapy may undergo surgery alone lesion resect negative margin reasonable functional result begin week 13 . Following surgery , patient unresectable lesion inadequate margin may receive radiotherapy week 15 . Patients bulky lesion surgically difficult site spine , skull , periacetabular pelvis ; poor response induction chemotherapy ; surgery would result unacceptable functional result may receive radiotherapy alone week 13-19 . Patients bulky lesion difficult site good clinical radiographic response induction therapy may receive radiotherapy primary site week 13-19 follow surgery involve site week 25 recovery course 11 chemotherapy . Patients microscopic residual disease plan pre-operative radiotherapy receive additional radiotherapy . CONTINUATION THERAPY ( WEEKS 15-36 ) : Patients receive vincristine IV day 1 week 15 , 16 , 21-24 , 27-30 , 33 , 34 ; topotecan hydrochloride IV 30 minute day 1-5 week 15 , 21 , 29 ; cyclophosphamide IV 1 hour day 1-5 week 15 , 21 29 day 1 week 23 , 27 , 33 ; ifosfamide IV 1 hour day 1-5 week 17 , 19 , 25 , 31 , 35 ; etoposide IV 1 hour day 1-5 week 17 , 19 , 25 , 31 , 35 ; doxorubicin hydrochloride IV 15 minute day 1 2 week 23 , 27 , 33 . Patients also receive G-CSF SC induction therapy . After completion study treatment , patient follow 10 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive , Peripheral</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Diagnosis extracranial Ewing sarcoma peripheral primitive neuroectodermal tumor bone soft tissue : Newly diagnose disease Disease confirm biopsy attempt complete partial resection Unplanned excision allow provided adequate imaging obtain prior surgery incompletely resect disease control local therapy No esthesioneuroblastoma Localized disease , include follow site : Chest wall tumor ipsilateral pleural effusion , ipsilateral positive pleural fluid cytology , ipsilateral pleural base secondary tumor nodule ; No contralateral pleural effusion pleural nodule Regional lymph node clinically suspicious confirm biopsy No distant lymph node metastases Extradural tumor arise bony skull No tumor arise intradural soft tissue intradural region spine No evidence metastatic disease , define follow : Lesions discontinuous primary tumor Lesions regional lymph node Lesions share body cavity primary tumor No evidence CT scan metastatic lung disease , define follow : One pulmonary nodule &gt; 1 cm diameter one nodule &gt; 0.5 cm diameter Pulmonary nodule resect find metastatic Ewing sarcoma allow Biopsy proven solitary nodule measure 0.5 1.0 cm multiple nodule measure 0.3 0.5 cm Solitary nodule measure &lt; 0.5 cm multiple nodule measure &lt; 0.3 cm allow unless biopsy prove metastatic ( biopsy require ) Karnofsky performance status ( PS ) 02 ( &gt; = 16 year old ) OR Lansky PS 02 ( &lt; 16 year old ) Creatinine clearance radioisotope glomerular filtration rate â‰¥ 70 mL/min OR serum creatinine base age/gender follow : 1 month &lt; 6 month old ( male females 0.4 mg/dL ) 6 month &lt; 1 year old ( male females 0.5 mg/dL ) 1 &lt; 2 year old ( male females 0.6 mg/dL ) 2 &lt; 6 year old ( male females 0.8 mg/dL ) 6 &lt; 10 year old ( male females 1.0 mg/dL ) 10 &lt; 13 year old ( male females 1.2 mg/dL ) 13 &lt; 16 year old ( males 1.5 mg/dL female 1.4 mg/dL ) &gt; = 16 year old ( males 1.7 mg/dL female 1.4 mg/dL ) AST ALT &lt; 2.5 time ULN age Total bilirubin = &lt; 1.5 time upper limit normal ( ULN ) age Shortening fraction &gt; = 27 % ECHO ejection fraction &gt; = 50 % radionuclide angiogram ( MUGA ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior chemotherapy radiotherapy No concurrent pegfilgrastim ( Neulasta ) sargramostim ( GMCSF ) No concurrent cancer chemotherapy immunomodulating agent , include steroid , unless use antiemetic</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>